ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BMK Benchmark Holdings Plc

45.90
1.80 (4.08%)
Last Updated: 16:19:17
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Holdings Plc LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.80 4.08% 45.90 45.20 46.00 45.90 45.90 45.90 18,767 16:19:17
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 169.74M -23.15M -0.0313 -14.66 339.36M

Benchmark Holdings PLC Sale of FishVet (6672R)

01/07/2020 7:00am

UK Regulatory


Benchmark (LSE:BMK)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Benchmark Charts.

TIDMBMK

RNS Number : 6672R

Benchmark Holdings PLC

01 July 2020

1 July 2020

Benchmark Holdings

("Benchmark" the "Company" or the "Group")

Sale of veterinary and diagnostic services business

Benchmark Holdings, the aquaculture genetics, health and advanced nutrition company, announces that it has completed the sale of its wholly owned subsidiary FVG Ltd. ("FishVet") to Pharmaq, part of the global animal health company Zoetis, for a total cash consideration of GBP14.4 - GBP14.7 million. The sale comprises Benchmark's veterinary and diagnostic services activities in the UK, Ireland, Norway and Chile. The final consideration will depend on certain final costs to be borne by Benchmark.

The transaction is another significant step in Benchmark's strategy to exit non-core areas and focus on its key disciplines in the global aquaculture markets. The sale of FishVet together with the sale of Improve International announced on 23 June, raised in aggregate c. GBP27.25m including GBP3.25m in deferred consideration, in line with expectations. The sale significantly strengthens the Group's financial position and liquidity. To date, the Company has sold or exited seven businesses generating up to GBP30.3m in cash proceeds including GBP3.75m in deferred consideration.

Having successfully exited these businesses as planned, the Company continues to progress the review of its vaccine strategy and the exit from its activities in companion animal products.

Trond Williksen, CEO, commented

"I am very pleased to announce this transaction, the proceeds of which together with those from the sale of Improve International last week, are in line with our expectations. These disposals represent a significant step forward in our strategy to become a streamlined, profitable business focused on our key areas of competency."

"The FishVet team is a highly talented group. I would like to thank every member of the team and wish them success in the future."

 
 For further information, please contact: 
 Benchmark Holdings plc                     benchmark@mphc.com 
 Trond Williksen, CEO 
 Septima Maguire, CFO 
 Ivonne Cantu, Investor Relations 
 
 
 Numis (Broker and NOMAD)                   Tel: 020 7260 1000 
 James Black, Freddie Barnfield, Duncan 
  Monteith 
 
 MHP Communications                         Tel: 07551 170 451 
 
   Katie Hunt, Reg Hoare, Alistair de Kare-Silver                          benchmark@mphc.com 

About Benchmark

Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DISFIFLEDVILIII

(END) Dow Jones Newswires

July 01, 2020 02:00 ET (06:00 GMT)

1 Year Benchmark Chart

1 Year Benchmark Chart

1 Month Benchmark Chart

1 Month Benchmark Chart

Your Recent History

Delayed Upgrade Clock